Serum deoxyribonucleases in patients with breast cancer

Spandidos, Demetrios Α.; G, Ramandanis; Garas, J; Kottaridis, S. D.

doi:10.1016/0014-2964(80)90036-5

Cited by 29 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low DNase activity was found in patients with malignant stomach, colon and pancreas cancer, and also malignant lymphoma, compared to healthy individuals [95,96]. Conversely, high serum DNase activity was observed in patients with breast [97] and oral cancers [98]. The study of different phenotypes of DNase I showed that the phenotype 2, with DNASE1*2 polymorphism, may potentially be a good predictor of the development of gastric and colorectal carcinoma, while no such association was found with other types of cancer.…”

Section: Dnase Activity As a Biomarkermentioning

confidence: 86%

Deoxyribonucleases and Their Applications in Biomedicine

et al. 2020

View full text Add to dashboard Cite

Extracellular DNA, also called cell-free DNA, released from dying cells or activated immune cells can be recognized by the immune system as a danger signal causing or enhancing inflammation. The cleavage of extracellular DNA is crucial for limiting the inflammatory response and maintaining homeostasis. Deoxyribonucleases (DNases) as enzymes that degrade DNA are hypothesized to play a key role in this process as a determinant of the variable concentration of extracellular DNA. DNases are divided into two families—DNase I and DNase II, according to their biochemical and biological properties as well as the tissue-specific production. Studies have shown that low DNase activity is both, a biomarker and a pathogenic factor in systemic lupus erythematosus. Interventional experiments proved that administration of exogenous DNase has beneficial effects in inflammatory diseases. Recombinant human DNase reduces mucus viscosity in lungs and is used for the treatment of patients with cystic fibrosis. This review summarizes the currently available published data about DNases, their activity as a potential biomarker and methods used for their assessment. An overview of the experiments with systemic administration of DNase is also included. Whether low-plasma DNase activity is involved in the etiopathogenesis of diseases remains unknown and needs to be elucidated.

show abstract

Section: Dnase Activity As a Biomarkermentioning

confidence: 86%

Deoxyribonucleases and Their Applications in Biomedicine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies showed that abnormal DNase levels occurred in association with a variety of diseases. A high serum DNase concentration was found in patients with renal failure [6,7]; advanced liver diseases [12]; acute haemorrhagic pancreatitis [13]; breast cancer [14]; oral cancer [15] and genitourinary cancer [16]. A low concentration of urine DNase was found in patients with xeroderma pigmentosum [17].…”

Section: Introductionmentioning

confidence: 99%

Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay

Macanović

Lachmann

1997

Clinical and Experimental Immunology

104

View full text Add to dashboard Cite

SUMMARYA new radial enzyme diffusion (RED) method for the measurement of DNase activity in serum and urine is described. The sensitivity of the assay is in the range of 15 . 6-500 ng/ml. The assay is based on the hydrolysis of double-stranded (ds) DNA (or nucleosomes) in agarose. The specificity of the reaction for DNase I was established by showing that either EDTA in the reaction buffer or G-actin abolished DNase activity. Being a functional assay, RED has advantages over radioimmunoassay (RIA) or ELISA, since antigenic assays may also measure complexes of DNase with actin. This method was used to measure DNase activity in the sera and urine of lupus-prone mice (NZB/NZW F 1 hybrids, aged 4-6 weeks). Serum DNase activity in these mice was significantly lower (mean 9 ng/ml) than in control, normal mice of the same age and sex (mean 37 ng/ml). Concentration of DNase in the urine of 4-6-week-old female NZB/NZW F 1 hybrids (24 ng/ml) was significantly lower then in control mice (521 ng/ml). The RED method was used to measure the concentration of actin as the DNase inhibitor in serum. G-actin in the presence of ATP binds DNase and inhibits its nucleolytic activity. Since ATP is necessary for the actin inhibition of DNase I, this shows that there is actin as well as DNase I in the serum. Actin is not only ATP-dependent, but also heat-labile. Heating the sera for 10 min at 50ЊC increases DNase activity. This is an alternative method for measuring the concentration of actin in the serum. An almost identical estimate of actin concentration in sera of normal mice was found from the difference of DNase activity in the presence or absence of ATP (mean actin concentration ¼ 21 ng/ml) or from the difference of DNase activity in heated and non-heated serum (mean actin concentration 18 ng/ml). We were not able to demonstrate DNase inhibitors in the urine of either control or NZB/W F 1 hybrid mice.

show abstract

“…DNase activity has been measured for several diseases, mainly in cancer patients. In patients with malignant lymphoma, 5 stomach and colon cancer, 6 and pancreatic cancer, 7 the DNase activity was lower than in persons without cancer, whereas in the patients with breast 8 and oral cancers, 9 high serum DNase activity was observed.…”

Section: Introductionmentioning

confidence: 90%

Deoxyribonuclease Activity and Circulating DNA Concentration in Blood Plasma of Patients with Prostate Tumors

Cherepanova

Тамкович

Bryzgunova

et al. 2008

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The DNase activity and circulating DNA (cirDNA) concentration in blood plasma of healthy donors, patients with chronic prostatitis, and patients with prostate tumors were analyzed. The concentration of the cirDNA from plasma was determined by PicoGreen fluorescent assay. DNase activity in blood was measured using the immunoassay based on the cleavage of a hapten-labeled 974-bp DNA substrate. The mean cirDNA concentration in the plasma of healthy donors was low (21 +/- 4 ng/mL total blood) and was accompanied by high DNase activity (0.17 +/- 0.04 U/mL blood). The mean cirDNA concentration was 90 ng/mL blood (10-234 ng/mL) in the patients with nonmalignant prostate tumors and 115 ng/mL blood (13-339 ng/mL) in those with prostate cancer. The mean DNase activity in blood plasma of the patients with prostate tumors was 0.06 U/mL blood (0-0.12 U/mL). The results obtained demonstrate that increased concentrations of cirDNA in blood of the patients with prostate tumors is accompanied by a decreased DNase activity, confirming our previous data that a low DNase activity in blood plasma of cancer patients is one reason for a high cirDNA concentration.

show abstract

Serum deoxyribonucleases in patients with breast cancer

Cited by 29 publications

References 5 publications

Deoxyribonucleases and Their Applications in Biomedicine

Deoxyribonucleases and Their Applications in Biomedicine

Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay

Deoxyribonuclease Activity and Circulating DNA Concentration in Blood Plasma of Patients with Prostate Tumors

Contact Info

Product

Resources

About